Skip to main content
Premium Trial:

Request an Annual Quote

Geneseeq Nabs CE Marks for Residual Disease and Cancer Early Detection Tests

NEW YORK – Cancer diagnostics firm Geneseeq Technology said Tuesday that both its multi-cancer minimal residual disease detection (MRD) and multi-cancer early detection (MCED) kits have been CE-marked for use in solid tumor patients.

The Toronto-based company said this will enable it to expand its global business operations and establish new partnerships in the European market.

Geneseeq's MRD detection kit, dubbed Shielding, employs an ultra-deep sequencing technology that the firm calls ATG-SEQ to detect low levels of circulating tumor DNA in patients' peripheral blood after surgical removal of their tumor.

The company has published data on the use of this approach to predict recurrence in lung cancer patients.

For early cancer detection, Geneseeq has developed an in vitro diagnostic kit using a highly sensitive next-generation sequencing-based technology, called MERCURY, to assess multiomic features of circulating free DNA that distinguish tumorigenesis in asymptomatic individuals.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.